Oral semaglutide vastly reduces heart attacks, strokes in people with type 2 diabetes. New England Journal of Medicine #AAC25
Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even alcohol cravings.…
Stem cell trial for early Alzheimer’ s disease begins at UTHealth Houston
A stem cell therapy trial aimed at reducing neuroinflammation in patients with presymptomatic Alzheimer’s disease is underway at UTHealth Houston. In Alzheimer’s disease, deposits of beta-amyloid and tau lead to…
A diabetes, heart failure and kidney disease medication (sotagliflozin) is the first of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and…
CDC Statement on Marburg Cases in Rwanda
CDC is aware of 26 individuals with Marburg virus disease, as confirmed by the Republic of Rwanda Ministry of Health. According to the Ministry, eight of those individuals have died.…
Estrogens play a hidden role in cancers, inhibiting a key immune cell
Estrogens are known to drive tumor growth in breast cancer cells that carry its receptors, but a new study by Duke Cancer Institute researchers unexpectedly finds that estrogens play a…
Blood test can help predict chronic lung disease in preterm babies
A blood test can help predict which preterm babies will go onto develop chronic lung disease, allowing for earlier diagnosis and more targeted treatments, according to a new study. The…
Inflammatory activity of rheumatoid arthritis linked to specific cognitive impairments
The inflammatory activity in the body caused by rheumatoid arthritis is linked to specific cognitive impairments, finds a small comparative study, published in the open access journal RMD Open. These…
Understanding the benefits of GLP-1 drugs beyond obesity
In a Perspective, Daniel Drucker highlights the growing body of evidence that hints at the potential of glucagon-like peptide-1 (GLP-1)-based medications in treating conditions other than diabetes and obesity, including…
When to trust an Artificial Intelligence AI model
Because machine-learning models can give false predictions, researchers often equip them with the ability to tell a user how confident they are about a certain decision. This is especially important…
Artificial intelligence outperforms clinical tests at predicting progress of Alzheimer’s disease
Cambridge scientists have developed an artificially-intelligent tool capable of predicting in four cases out of five whether people with early signs of dementia will remain stable or develop Alzheimer’s disease.…